Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis

被引：431
|
作者：
Kuo, Phillip H.
Kanal, Emanuel
Abu-Alfa, Ali K.
Cowper, Shawn E.
机构：
[1] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Dermatol & Pathol, New Haven, CT 06520 USA
[4] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA USA
来源：
RADIOLOGY | 2007年 / 242卷 / 03期
关键词：
D O I：
10.1148/radiol.2423061640
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
While at this time there are more questions than answers, the recognition of an epidemiologic association between the administration of gadolinium-based MR contrast agents and the development of nephrogenic systemic fibrosis prompts caution in the use of these agents in the setting of renal disease. © RSNA, 2007.
引用
收藏
页码：647 / 649
页数：3
相关论文
共 50 条
  • [1] Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
    Abu-Alfa, Ali K.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (03) : 188 - 198
  • [2] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Penfield, Jeffrey G.
    PEDIATRIC NEPHROLOGY, 2008, 23 (12) : 2121 - 2129
  • [3] Gadolinium-based Contrast Agents and Nephrogenic Systemic Fibrosis Response
    Semelka, Richard C.
    Altun, Ersan
    Wertman, Rebecca
    Martin, Diego R.
    Leyendecker, John R.
    O'Malley, Ryan B.
    Parsons, Daniel J.
    Fuller, Edwin R., III
    Mitchell, Donald G.
    RADIOLOGY, 2009, 250 (03) : 959 - U457
  • [4] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Jeffrey G. Penfield
    Pediatric Nephrology, 2008, 23 : 2121 - 2129
  • [5] MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents Gadolinium Retention and Nephrogenic Systemic Fibrosis
    McDonald, Jennifer S.
    McDonald, Robert J.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2020, 28 (04) : 497 - +
  • [6] Nephrogenic systemic fibrosis and gadolinium-based contrast media
    Andrejak, Michel
    Thuillier, Delphine
    Lok, Catherine
    Gras-Champel, Valerie
    THERAPIE, 2007, 62 (02): : 169 - 172
  • [7] Nephrogenic systemic fibrosis risk: Is there a difference between gadolinium-based contrast agents?
    Penfield, Jeffrey G.
    Reilly, Robert F.
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 129 - 134
  • [8] Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents - A status
    Heinrich, M.
    Uder, M.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2007, 179 (06): : 613 - 617
  • [9] Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents
    Kitajima, Kazuhiro
    Maeda, Tetsuo
    Watanabe, Sanae
    Ueno, Yoshiko
    Sugimura, Kazuro
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (09) : 806 - 811
  • [10] Nephrogenic systemic fibrosis (NSF) and gadolinium-based contrast media
    Ngoya, P. S.
    Vawda, Z.
    Lotz, J. W.
    SA JOURNAL OF RADIOLOGY, 2013, 17 (03): : 106 - 107
12345